Table 3:
Phase 1 Cannabis Outcomes
| SIM (n=34) | SEQ (n=33) | Summary Measure (SIM vs. SEQ) |
Test Statistic | |
|---|---|---|---|---|
| Primary abstinence outcome: weeks of continuous abstinence | ||||
| ≥ 1 week of documented abstinence, N (%) | 7 (20.6%) | 12 (36.4%) | OR (95% CI) 0.45 (0.15, 1.35) |
χ2(1) = 2.01, p = 0.16 |
| Weeks of continuous documented abstinence among those with ≥ 1 week, Mean (SD) | 5.9 (4.0) | 6.1 (3.7) | Means Ratio (95% CI) 0.97 (0.66,1.42) |
χ2(1) = 0.03, p = 0.87 |
| Secondary outcomes | ||||
| Point-prevalence documented abstinence (week 12) follow up assessment), N(%) | 7 (20.6%) | 6 (18.2%) | χ2(1) = 0.06, p = 0.80 |
|
| Self-report of abstinence (days of use = 0) during weeks 9–12a, N(%) | 6 (17.7%) | 8 (24.2%) | OR (95% CI) 0.67 (0.2, 2.2) |
χ2(1) = 0.44, p = 0.51 |
| ≥ 50% reduction in days of use (intake vs. final 4 weeks)a, N(%) | 9 (26.5%) | 15 (45.5%) | χ2(1) = 2.63, p = 0.11 |
a
self-report data available for n=22 per condition, missing data considered positive for cannabis use.
ETX: end of treatment; SEQ: sequential treatment condition; SIM: simultaneous treatment condition.